210 related articles for article (PubMed ID: 26968844)
1. Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia.
Damjanov N; Shehhi WA; Huang F; Kotak S; Burgos-Vargas R; Shirazy K; Bananis E; Szumski A; Llamado LJ; Mahgoub E
Rheumatol Int; 2016 May; 36(5):643-51. PubMed ID: 26968844
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of etanercept in patients from Latin America, Central Europe and Asia with early non-radiographic axial spondyloarthritis.
Wei JC; Tsai WC; Citera G; Kotak S; Llamado L
Int J Rheum Dis; 2018 Jul; 21(7):1443-1451. PubMed ID: 27863065
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial.
Braun J; van der Horst-Bruinsma IE; Huang F; Burgos-Vargas R; Vlahos B; Koenig AS; Freundlich B
Arthritis Rheum; 2011 Jun; 63(6):1543-51. PubMed ID: 21630245
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial.
van der Heijde D; Braun J; Dougados M; Sieper J; Pedersen R; Szumski A; Koenig AS
Rheumatology (Oxford); 2012 Oct; 51(10):1894-905. PubMed ID: 22772319
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials.
Baraliakos X; Koenig AS; Jones H; Szumski A; Collier D; Bananis E
J Rheumatol; 2015 Aug; 42(8):1418-26. PubMed ID: 26077401
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement.
Braun J; Pavelka K; Ramos-Remus C; Dimic A; Vlahos B; Freundlich B; Koenig AS
J Rheumatol; 2012 Apr; 39(4):836-40. PubMed ID: 22337244
[TBL] [Abstract][Full Text] [Related]
7. Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial.
Kemeny L; Amaya M; Cetkovska P; Rajatanavin N; Lee WR; Szumski A; Marshall L; Mahgoub EY; Aldinç E
BMC Dermatol; 2015 May; 15():9. PubMed ID: 25994179
[TBL] [Abstract][Full Text] [Related]
8. Etanercept in the longterm treatment of patients with ankylosing spondylitis.
Dijkmans B; Emery P; Hakala M; Leirisalo-Repo M; Mola EM; Paolozzi L; Salvarani C; Sanmarti R; Sibilia J; Sieper J; Van Den Bosch F; van der Heijde D; van der Linden S; Wajdula J
J Rheumatol; 2009 Jun; 36(6):1256-64. PubMed ID: 19411393
[TBL] [Abstract][Full Text] [Related]
9. High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study).
Navarro-Sarabia F; Fernández-Sueiro JL; Torre-Alonso JC; Gratacos J; Queiro R; Gonzalez C; Loza E; Linares L; Zarco P; Juanola X; Román-Ivorra J; Martín-Mola E; Sanmartí R; Mulero J; Diaz G; Armendáriz Y; Collantes E
Rheumatology (Oxford); 2011 Oct; 50(10):1828-37. PubMed ID: 21700683
[TBL] [Abstract][Full Text] [Related]
10. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
van der Heijde D; Da Silva JC; Dougados M; Geher P; van der Horst-Bruinsma I; Juanola X; Olivieri I; Raeman F; Settas L; Sieper J; Szechinski J; Walker D; Boussuge MP; Wajdula JS; Paolozzi L; Fatenejad S;
Ann Rheum Dis; 2006 Dec; 65(12):1572-7. PubMed ID: 16968715
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
Davis JC; Van Der Heijde D; Braun J; Dougados M; Cush J; Clegg DO; Kivitz A; Fleischmann R; Inman R; Tsuji W;
Arthritis Rheum; 2003 Nov; 48(11):3230-6. PubMed ID: 14613288
[TBL] [Abstract][Full Text] [Related]
12. [A multicenter, double-blind, randomized, placebo-controlled clinical trial of etanercept treatment of Chinese patients with active ankylosing spondylitis].
Huang F; Zhang J; Zheng Y; Xu JH; Li XF; Wu HX; Chen ZW; Zhao Z; Zhang YM
Zhonghua Nei Ke Za Zhi; 2011 Dec; 50(12):1043-7. PubMed ID: 22333175
[TBL] [Abstract][Full Text] [Related]
13. [Sulfasalazine in ankylosing spondylitis: a prospective, randomized, double-blind placebo-controlled study and comparison with other controlled studies].
Schmidt WA; Wierth S; Milleck D; Droste U; Gromnica-Ihle E
Z Rheumatol; 2002 Apr; 61(2):159-67. PubMed ID: 12056293
[TBL] [Abstract][Full Text] [Related]
14. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison.
Combe B; Codreanu C; Fiocco U; Gaubitz M; Geusens PP; Kvien TK; Pavelka K; Sambrook PN; Smolen JS; Wajdula J; Fatenejad S;
Ann Rheum Dis; 2006 Oct; 65(10):1357-62. PubMed ID: 16606651
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.
Davis JC; van der Heijde DM; Braun J; Dougados M; Clegg DO; Kivitz AJ; Fleischmann RM; Inman RD; Ni L; Lin SL; Tsuji WH
Ann Rheum Dis; 2008 Mar; 67(3):346-52. PubMed ID: 17967833
[TBL] [Abstract][Full Text] [Related]
16. Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies.
van der Horst-Bruinsma IE; Zack DJ; Szumski A; Koenig AS
Ann Rheum Dis; 2013 Jul; 72(7):1221-4. PubMed ID: 23264358
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
Calin A; Dijkmans BA; Emery P; Hakala M; Kalden J; Leirisalo-Repo M; Mola EM; Salvarani C; Sanmartí R; Sany J; Sibilia J; Sieper J; van der Linden S; Veys E; Appel AM; Fatenejad S
Ann Rheum Dis; 2004 Dec; 63(12):1594-600. PubMed ID: 15345498
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.
Dougados M; Wood E; Combe B; Schaeverbeke T; Miceli-Richard C; Berenbaum F; Koppiker N; Dubanchet A; Logeart I
Arthritis Res Ther; 2014 Nov; 16(6):481. PubMed ID: 25428762
[TBL] [Abstract][Full Text] [Related]
19. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
Davis JC; van der Heijde DM; Braun J; Dougados M; Cush J; Clegg D; Inman RD; Kivitz A; Zhou L; Solinger A; Tsuji W
Ann Rheum Dis; 2005 Nov; 64(11):1557-62. PubMed ID: 15843448
[TBL] [Abstract][Full Text] [Related]
20. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
Braun J; McHugh N; Singh A; Wajdula JS; Sato R
Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]